-
Alisertib (MLN8237) is an
orally available , investigational, reversible, ATP-competitive,
selective aurora A
kinase inhibitor developed by Takeda. Inhibition...
- Laboratories)
alinidine (INN)
alipamide (INN)
alipogene tiparvovec (INN)
alisertib (INN, USAN)
aliskiren (USAN)
alisporivir INN, USAN)
alitretinoin (INN)...
- Romidepsin,
Brentuximab vedotin, Belinostat, Bendamustine, lenalidomide, and
alisertib have
shown activity against CTCL, NOS and are
being further studied in...
- anti-carcinogenic agent. The
therapeutic approach with a
triple combination of
Alisertib and
Trametinib with
Etomoxir proved to be beneficial,
inducing regression...
-
proficiency of the
tumor cells.
Inhibition of
AURKA and HDAC6
activity by
alisertib and
tubastatin A in
xenograft models of
breast cancer has led to a decrease...
